1naresh
Array ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) ) 1nareshArray ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) )Table 2:Tumor extension and abnormal signal intensity in adjacent laryngeal cartilages
Site Glottic Lesion (n = 36) Supraglottic Lesion (n = 28) Patients* Glottis Primary location 22 22 (34) Supraglottis 11 Primary location 11 (17) Subglottis 16 9 25 (39) PES 5 19 24 (37) PGS 2 15 17 (27) Thyroid cartilage at anterior commissure 14 6 20 (31) Extralaryngeal extension at anterior commissure 2 3 5 (8) Thyroid cartilage 6 7 13 (20) Extralaryngeal extension at thyroid 1 2 3 (5) Cricoid cartilage 5 5 10 (16) Extralaryngeal extension at cricoid 0 1 1 (2) Hypopharynx 2 10 12 (19)
* Data are numbers of patients affected by tumor extension at the site indicated. Numbers in parentheses are percentages of the total (n = 64 patients).